Diagnostic and Predictive Power of Plasma Proteins in Alzheimer's Disease: a Cross-sectional and Longitudinal Study in China

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jul 30

PMID 39080359

Authors

Wei Li

Lin Sun

Ling Yue

Shifu Xiao

Affiliations

Soon will be listed here.

Abstract

Convenient and effective biomarkers are essential for the early diagnosis and treatment of Alzheimer's disease (AD). In the cross-sectional study, 103 patients with AD, 82 patients with aMCI and 508 normal controls (NC) were enrolled. The single-molecule array (Simoa) technique was used to assess the levels of plasma proteins, including NfL, T-tau, P-tau-181, Aβ40, Aβ42. Montreal Cognitive Assessment (MoCA) was used to assess the overall cognitive function of all subjects. Moreover, Amyloid PET and structural head MRI were also performed in a subset of the population. In the follow-up, the previous 508 normal older adults were followed up for two years, then COX regression analysis was used to investigate the association between baseline plasma proteins and future cognitive outcomes. NfL, T-tau, P-tau-181, Aβ40, Aβ42 and Aβ42/40 were altered in AD dementia, and NfL, Aβ42 and Aβ42/40 significantly outperformed all plasma proteins in differentiating AD dementia from NC, while NfL and Aβ42/40 could effectively distinguish between aMCI and NC. However, only plasma NfL was associated with future cognitive decline, and it was negatively correlated with MoCA (r = - 0.298, p < 0.001) and the volume of the left globus pallidus (r = - 0.278, p = 0.033). Plasma NfL can help distinguish between cognitively normal and cognitively impaired individuals (MCI/dementia) at the syndrome level. However, since we have not introduced other biomarkers for AD, such as PET CT or cerebrospinal fluid, and have not verified in other neurodegenerative diseases, whether plasma NFL can be used as a biomarker for AD needs to be further studied and explored.

References

Zetterberg H, Burnham S . Blood-based molecular biomarkers for Alzheimer's disease. Mol Brain. 2019; 12(1):26. PMC: 6437931. DOI: 10.1186/s13041-019-0448-1. View

Olsson B, Portelius E, Cullen N, Sandelius A, Zetterberg H, Andreasson U . Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurol. 2018; 76(3):318-325. PMC: 6440232. DOI: 10.1001/jamaneurol.2018.3746. View

Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X . The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. Int J Geriatr Psychiatry. 2013; 29(7):713-9. DOI: 10.1002/gps.4053. View

Villemagne V, Fodero-Tavoletti M, Masters C, Rowe C . Tau imaging: early progress and future directions. Lancet Neurol. 2014; 14(1):114-24. DOI: 10.1016/S1474-4422(14)70252-2. View

Lin Y, Lee W, Wang S, Fuh J . Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep. 2018; 8(1):17368. PMC: 6255914. DOI: 10.1038/s41598-018-35766-w. View

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

Atri A . The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019; 103(2):263-293. DOI: 10.1016/j.mcna.2018.10.009. View

Hu Y, He S, Duan Q, Khatoon S, Iqbal K, Grundke-Iqbal I . Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett. 2002; 320(3):156-60. DOI: 10.1016/s0304-3940(02)00047-2. View

Scheltens P, Blennow K, Breteler M, De Strooper B, Frisoni G, Salloway S . Alzheimer's disease. Lancet. 2016; 388(10043):505-17. DOI: 10.1016/S0140-6736(15)01124-1. View

10.

Cohen A, Landau S, Snitz B, Klunk W, Blennow K, Zetterberg H . Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Mol Cell Neurosci. 2018; 97:3-17. DOI: 10.1016/j.mcn.2018.12.004. View

11.

Sala-Llonch R, Llado A, Fortea J, Bosch B, Antonell A, Balasa M . Evolving brain structural changes in PSEN1 mutation carriers. Neurobiol Aging. 2015; 36(3):1261-70. DOI: 10.1016/j.neurobiolaging.2014.12.022. View

12.

Schindler S, Bollinger J, Ovod V, Mawuenyega K, Li Y, Gordon B . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17):e1647-e1659. PMC: 6946467. DOI: 10.1212/WNL.0000000000008081. View

13.

Aristieta A, Gittis A . Distinct globus pallidus circuits regulate motor and cognitive functions. Trends Neurosci. 2021; 44(8):597-599. PMC: 8562495. DOI: 10.1016/j.tins.2021.06.001. View

14.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

15.

Falgas N, Ruiz-Peris M, Perez-Millan A, Sala-Llonch R, Antonell A, Balasa M . Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Hum Brain Mapp. 2020; 41(8):2004-2013. PMC: 7267898. DOI: 10.1002/hbm.24925. View

16.

Hampel H, Burger K, Teipel S, Bokde A, Zetterberg H, Blennow K . Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008; 4(1):38-48. DOI: 10.1016/j.jalz.2007.08.006. View

17.

Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P . Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):71. PMC: 6064615. DOI: 10.1186/s13195-018-0404-9. View

18.

Baiardi S, Quadalti C, Mammana A, Dellavalle S, Zenesini C, Sambati L . Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022; 14(1):153. PMC: 9555092. DOI: 10.1186/s13195-022-01093-6. View

19.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

20.

Chien D, Bahri S, Szardenings A, Walsh J, Mu F, Su M . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2012; 34(2):457-68. DOI: 10.3233/JAD-122059. View